Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education

British Journal of Clinical Pharmacology

Volumn 67, Issue 3, 2009, Pages 355-362

  Selmer, Randi ^a   Sakshaug, Solveig ^a   Skurtveit, Svetlana ^a,b   Furu, Kari ^a   Tverdal, Aage ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Education; Pharmacoepidemiology; Prescription database; Risk factors; Socioeconomic status; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACADEMIC ACHIEVEMENT; ADULT; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS;

ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NORWAY; PROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 62949094892     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03360.x     Document Type: Article

References (24)

1. Mackenbach JP, Bos V, Andersen O, Cardano M, Costa G, Harding S, Reid A, Hemström Ö, Valkonen T, Kunst AE. Widening socioeconomic inequalities in mortality in six Western European countries. Int J Epidemiol 2003 32 : 830 7.
2. Strand BH, Tverdal A. Can cardiovascular risk factors and lifestyle explain the educational inequalities in mortality from ischaemic heart disease and from other heart diseases? 26 year follow up of 50,000 Norwegian men and women. J Epidemiol Community Health 2004 58 : 705 9.
3. Strand BH, Tverdal A. Trends in educational inequalities in cardiovascular risk factors: a longitudinal study among 48,000 middle-aged Norwegian men and women. Eur J Epidemiol 2006 21 : 731 9.
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori S, Pyörälä K, Reiner Z, Ruilope L, Sans-Menendez S, Reimer W, Weissberg P, Wood D, Yarnell J, Zamarano J. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehabil 2007 14 : E1 40.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 : 1383 9.
6. Abramson J, Wright JM. Are lipid-lowering guidelines evidence-based? Lancet 2007 369 : 168 9.
7. Nomesco. Health Statistics in the Nordic Countries 2006. Copenhagen, Denmark : Nomesco, 2008, 208. Available at http://nomesco-eng.nom-nos.dk/ default.asp?side=88 (last accessed 19 December 2008).
8. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005 60 : 543 51.
9. Næss O, Søgaard AJ, Arnesen E, Beckstrøm AC, Bjertness E, Engeland A, Hjort PF, Holmen J, Magnus P, Njølstad I, Tell GS, Vatten L, Vollset SE, Aamodt G. Cohort profile: cohort of Norway (CONOR). Int J Epidemiol 2008 37 : 481 5.
10. CONOR questions, 2008. Available at http://www.fhi.no/dav/6feb85397d.xls (last accessed 19 December 2008).
11. Furu K, Skurtveit S, Rosvold E. Drug use questions in Norwegian health surveys - response rate and agreement between specific and open-ended questions. Nor J Epidemiol 2003 13 : 147 54.
12. Education register- Statistics Norway, 2007. Available at http://www.ssb.no/english/subjects/04/01/utniv-en/ (last accessed 19 December 2008).
13. Norwegian Prescription Database, 2008. Available at http://www.norpd.no/ (last accessed 19 December 2008).
14. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - new opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008 18 : 129 36.
15. Guidelines for ATC Classification and DDD Assignment 2008. Oslo, Norway : WHO Collaborating Centre for Drug Statistics Methodology, 2007.
16. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004 159 : 702 6.
17. Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 2004 255 : 494 502.
18. Hartz I, Eggen AE, Grimsgaard S, Skjold F, Njølstad I. Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromsø study 2001. Eur J Clin Pharmacol 2004 60 : 643 9.
19. Weitoft GR, Rosen M, Ericsson O, Ljung R. Education and drug use in Sweden - a nationwide register-based study. Pharmacoepidemiol Drug Saf 2008 17 : 1020 8.
20. Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-reducing treatments: a randomized trial. Ann Intern Med 2007 146 : 848 56.
21. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J, Sørensen HT. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005 60 : 534 42.
22. Rasmussen JN, Gislason GH, Rasmussen S, Abildstrøm SZ, Schramm TK, Køber L, Diderichsen F, Osler M, Torp-Pedersen C, Madsen M. Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Community Health 2007 61 : 1091 7.
23. Haga A, Sverre JM. Pricing and reimbursement of pharmaceuticals in Norway. Eur J Health Econ 2002 3 : 215 20.
24. Selection bias. In : Epidemiologic Research - Principles and Quantitative Methods, ed. Kleinbaum DG, Kupper LL, Morgenstern H. New York : Van Nostrand Reinhold 1982 194 219.